Fisher Wallace Labs develops non-invasive neuromodulation devices designed to treat mental health conditions through cranial electrotherapy stimulation. The company’s flagship system delivers low-level electrical stimulation via electrodes placed on the head and is cleared for home use. Its technology is intended to provide an alternative or complement to pharmacological treatment. Fisher Wallace Labs positions its device within regulated medical device frameworks.

The technology applies gentle electrical currents across the head to modulate neural activity associated with mood and sleep regulation. Stimulation protocols are designed for repeated use, allowing patients to self-administer treatment outside clinical settings. The system does not involve neural recording or invasive components, focusing instead on simplicity and accessibility. This approach enables consistent therapy delivery with minimal setup or supervision.

Fisher Wallace Labs targets individuals with depression, anxiety, and insomnia seeking non-pharmacological treatment options. The device is prescribed or recommended within established clinical pathways but used independently at home. Its focus reflects broader interest in accessible, non-invasive neuromodulation therapies for chronic mental health conditions.